Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
NCT ID NCT05455931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. The goal was to understand how the drug works in everyday clinical practice, outside of a controlled trial setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Poteligeo (mogamulizumab)
What this could lead to
If successful, this study could provide real-world evidence on how Poteligeo improves symptoms and quality of life for people with these rare skin lymphomas.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is small (73 participants) and completed, so findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES AND SÉZARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Ospedali Riuniti Do Ancona
Ancona, Italy
-
Azienda Ospedaliero- Universitaria Careggi
Florence, Italy
-
Clatterbridge Hospital - Wirral University Teaching Hospital Nhs Foundation Trust
Bebington, United Kingdom
-
Colombia University Medical Center
New York, New York, 10032, United States
-
Ematologia Policlinico di Milano
Milan, Italy
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98105, United States
-
Hospital Del Mar
Barcelona, Spain
-
Hospital Universitari de Bellvitge
Barcelona, Spain
-
IFO-San Gallicano IRCCS
Rome, Italy
-
IRCCS A.O.U. Policlinico S. Orsola - Malpighi
Bologna, Italy
-
Inova Dwight and Martha Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Leids Universitair Medisch Centrum (LUMC)
Leiden, Netherlands
-
Nottingham University Hospitals NHS Trust - Nottingham City Hospital
Nottingham, United Kingdom
-
Sheikh Shakhbout Medical City
Abu Dhabi, Abu Dhabi Emirate, 11001, United Arab Emirates
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
The Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States
-
Universita Cattolica del Sacro Cuore - Policlinico Universitario Agostino Gemelli
Rome, Italy
-
University Hospital Birmingham
Birmingham, United Kingdom
-
Washington University School of Medicine
St Louis, Missouri, 63108, United States